Longevity Economy: The Rise of Healthspan Extension and Its Societal Implications
In 2023, the global population of those aged 50 and over surpassed that of children under 15, marking a new era for the longevity economy.
Redefining Aging: A Treatable Condition
In laboratories from South San Francisco to Cambridge, a coordinated scientific effort is underway, backed by tens of billions in venture capital, to recast aging as a treatable condition. This initiative is led by molecular biologists and computational geneticists who are exploring the possibility of healthspan extension. The technical term often used in these circles is 'longevity,' while the more ambitious subtext hints at the quest for immortality. Despite these ambitious goals, the gap between promise and evidence remains significant. Many celebrated longevity drugs have shown underwhelming results in human trials. The notable breakthrough of the past year is not a drug but a gene therapy that is activated by an antibiotic, illustrating the complex and nascent stage of this field.
The technical approach to treating aging involves looking at it as a systems failure to be debugged, rather than mere wear and tear. This perspective shifts the focus from curing diseases like heart disease or cancer to addressing the underlying mechanisms of aging itself. The term 'healthspan extension' captures this shift, emphasizing the quality of life over mere lifespan increase. However, the infrastructure to support this vision—pensions, housing, and care work—remains outdated, designed for people who traditionally lived into their seventies.
The implications of redefining aging are profound for the industry. The longevity economy is estimated to contribute approximately $45 trillion to the global GDP, presenting the largest growth opportunity of the century. However, the market currently designs and markets for this demographic poorly, failing to capture the full potential of this economic shift. Stephen Johnston, co-founder of Aging2.0, emphasizes the need for systems redesign rather than isolated technological fixes. Johnston argues that aging should be seen as a system to be redesigned, pointing to the need for integrating AI to scale preventive care and address ageism.
From a broader perspective, the conversation around longevity and aging needs to move beyond the cellular level to consider the social systems at play. As Johnston notes, aging is a social system before it is a cellular one. The societal implications of extending healthspan are vast, raising questions about equity, access, and the very fabric of generational turnover. As we stand on the cusp of potentially extending human life significantly, we must also ask what kind of society we want to create for those additional years.
Stephen Johnston and the Aging2.0 Ecosystem
Stephen Johnston, co-founder of Aging2.0, has been pivotal in addressing the challenges of aging from a systems perspective. With a background in economics from Cambridge and an MBA from Harvard, Johnston's career trajectory took him from European-American trade policy to the rise and fall of Nokia. His experience with technology hype cycles led him to recognize the systemic failures in addressing aging. In 2012, alongside Katy Fike, he founded Aging2.0, a global network that grew to encompass over 30,000 people across 79 chapters in 23 countries before its acquisition in 2022.
Johnston's insight into the aging sector stems from a fundamental observation: even families with unlimited financial resources struggle to assemble coherent solutions for caregiving. This realization highlighted the absence of an ecosystem that could support aging populations effectively. Aging2.0 was built to fill this gap, focusing on three megatrends: the datafication of the individual, innovation within the home, and the return of social infrastructure. These trends emphasize the need for continuous physiological monitoring, home-based innovations, and the rebuilding of community and care networks.
The numbers behind these trends are staggering. In 2023, the global population shifted, with people aged 50 and over outnumbering children under 15 for the first time. This demographic shift is transforming global population pyramids into columns, and eventually, mushrooms. While some view this as a crisis, Johnston sees it as a market opportunity. The longevity economy, driven by the economic power of the 50-plus demographic, represents a $45 trillion contribution to the global GDP. However, this opportunity is currently underserved by an industry that designs poorly for this demographic.
Johnston's approach calls for moving beyond fragmented policy solutions to capture value across economic and social dimensions. This involves leveraging AI for preventive care and addressing the pervasive issue of ageism, which imposes significant economic costs. The future of aging will depend on our ability to redesign social systems to accommodate longer, healthier lives, ensuring that longevity benefits are equitably distributed across society.
The Heart Seat: A Revolution in Preventive Medicine
Casana, founded by Nicholas Conn from the Rochester Institute of Technology and led by CEO Austin McChord, is transforming preventive medicine with the innovative Heart Seat. Unlike traditional medical devices, the Heart Seat integrates clinical-grade sensors into a toilet seat, allowing for seamless and continuous health monitoring. This device captures an ECG-style trace of cardiac electrical activity, measures blood oxygen levels, and tracks body weight, all without requiring user compliance beyond the natural act of sitting on a toilet.
The technical ingenuity of the Heart Seat lies in its integration of multiple sensor technologies. Electrodes embedded in the seat capture cardiac data, while photoplethysmography sensors measure blood oxygenation and pulse waveform optically. Force sensors track weight changes. This passive monitoring approach addresses the common failure mode of remote patient monitoring: human compliance. By embedding health monitoring into a daily activity, the Heart Seat eliminates the need for manual intervention, ensuring consistent and reliable data collection.
The implications for the healthcare industry are significant. In May 2023, the Heart Seat received FDA clearance for measuring heart rate and blood oxygen saturation, marking a pivotal moment in age tech. With over $56 million raised from investors like General Catalyst and Morningside, Casana is pursuing further clearances, including non-invasive blood pressure monitoring. The ability to gather continuous, longitudinal health data from real-life settings could revolutionize how we approach preventive care, allowing for early detection of conditions like congestive heart failure and stroke.
As we look to the future, the Heart Seat exemplifies the shift towards integrating health monitoring into everyday life. This approach not only enhances individual health outcomes but also offers a model for how technology can seamlessly blend into our environments. By prioritizing user-friendly designs that require minimal effort, we can harness the power of data to improve healthspan and quality of life for aging populations.